Lancet Journal: Lower risk of death from new crowns of metformin takers Randomised trials will open...

In the early stages of the outbreak, we have noted that patients with underlying diseases such as diabetes, as well as obese people, are at higher risk of severe illness after contracting the new coronavirus.
Taking into account that both diabetes and obesity are chronic inflammatory states, and metformin has been shown to improve obesity-related inflammation and cytokines, this classic old drug has no "god" effect in the new crown, and has naturally received attention.
there have been small studies that have shown that metformin is associated with a reduced risk of death from the new crown.
recently, The Lancet Healthy Health officially published a large-scale study showing that metformin significantly reduces the risk of death from neo-coronary deaths in women by 21-24%, one of the world's largest observational studies of neo-coronavirus disease (COVID-19).
Screenshot Source: The Lancet Healthy Longevity study, led by the University of Minnesota School of Medicine, included 6,267 adult patients from a medical database called UHG who were diagnosed with COVID-19 by nucleic acid testing between January 1 and June 7, 2020, and were hospitalized with type 2 diabetes or obesity.
3,302 (52.8 per cent) of them were women.
database covers COVID-19 patient data for different ages, races and regions in all 50 U.S. states.
, author of the study and a researcher at the University of Minnesota School of Medicine, points to one of the data advantages: "There are very few large databases that cover different geographic regions.
" In all patient groups, there was no significant association between metformin use (defined as at least 90 days of prescription records for 12 months of diagnosis of COVID-19) and reduced mortality, using risk stratization models or preference matching score statistics.
but when only female patient data were analyzed, statistical differences emerged.
In the risk stratization model, metformin was associated with a 21.5% reduced risk of COVID-19 death in women, and metformin was associated with a 24.1% reduced risk of death in women on a tendency matching score.
metformin had no significant effect on the risk of COVID-19 death in men.
In different models, the risk of death was lower in female patients (green column) in the subgroup COVID-19 (Photo Source: Reference 1) The team noted in the paper that metformin reduced inflammation and immunomodulation was more pronounced in women.
refore, "it has been observed that metformin has a greater potential protective effect on women, which may indicate that reducing inflammation is a key mechanism for metformin to reduce the risk of COVID-19."
study's author, Dr. Carolyn Bramante of the University of Minnesota School of Medicine, said, "Such observational studies do not amount to a conclusion, but rather a process of adding evidence."
we still need more research.
" Although several new crown vaccines have shown good protection in Phase 3 trials, and several innovative treatments for COVID-19 have made positive progress, the evaluation of commonly used drugs with good safety against the virus has not been forgotten.
study is a positive example.
According to a press release from the University of Minnesota School of Medicine, the research team has submitted and approved AND (New Drugs for Clinical Research) applications to the FDA, and a multi-center, forward-looking randomized clinical trial to assess the effectiveness of metformin for COVID-19 treatment and prevention is scheduled to begin around mid-December.
review published in the same journal, The Lancet- Ageing Health, points out that in diabetics, whether improved clinical outcomes are a benefit of blood sugar control itself or an advantage of sugar-lowering drugs has been a matter of discussion.
the study used cross-ratios of different statistical models, the effects of metformin were relatively well determined.
But there are uncontrolled confidants in observational studies, such as the fact that metformin prescription records are not equivalent to actual drug use, that treatment options vary from center to center, and so on, and that the true effects of the drug need to be verified by randomized trials.
given the low price of metformin and the significant health impact of COVID-19, it would be cost-effective if proven in clinical trials.
can this classic old medicine bring welcome data? We'll see.
: s1. Carolyn T Bramante, et al., (2020). Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysiss. The Lancet Healthy Longevity, DOI: Stefano Del Prato, et al., (2020). Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19?. The Lancet Healthy Longevity, DOI: Study finds metformin reduced COVID-19 death risks in women. Retrieved December 4, 2020, from。